Company: MDCXW
Filing Date: 2025-09-29
Form Type: S-1
Source: 0001062993-25-015841
Chunk: 192

Company: Medicus Pharma Ltd.
Filing Date: 2025-09-29
Form: S-1
Chunk 192
---
 time of exercise there is no qualified offering statement or effective registration statement, or the offering circular or prospectus, as applicable, contained therein is not available for the issuance of the underlying shares to the holder, in lieu of making the cash payment otherwise contemplated to be made to us upon such exercise in payment of the aggregate exercise price, the holder may elect instead to receive upon such exercise (either in whole or in part) the net number of common shares determined according to a formula set forth in the full text of the Regulation A Warrant.

No fractional shares or scrip representing fractional shares shall be issued upon the exercise of the Regulation A Warrants. As to any fraction of a share which the holder would otherwise be entitled to purchase upon such exercise, we shall, at our election, either pay a cash adjustment in respect of such fraction in an amount equal to such fraction multiplied by the exercise price of the Regulation A Warrants or round the number of shares to be received by the holder up to the next whole number.

The Regulation A Warrants contain a contractual provision stating that all questions concerning the construction, validity, enforcement and interpretation of the Regulation A Warrants are governed by and construed and enforced in accordance with the internal laws of the State of New York, without regard to the principles of conflicts of law.

This summary of the Regulation A Warrants is not complete, and is qualified in its entirety by, the full text of the Regulation A Warrants and Warrant Agency Agreement in respect of the Regulation A Warrants, copies of which have been filed with the SEC as exhibits to the registration statement of which this prospectus forms a part and are incorporated in this prospectus by reference.

June 2030 Warrants

As of September 22, 2025, we had 2,260,000 June 2030 Warrants outstanding. Each warrant is exercisable for one common share at an exercise price of $3.10. The June 2030 Warrants were issued on June 2, 2025 in connection with our May 2025 Unit Offering and are exercisable at any time for a period of five years following the date of issuance, expiring on or prior to 5:00 pm ET on June 3, 2030.

The number of June 2030 Warrants outstanding, and the exercise price of those securities, will be adjusted proportionately in the event of a consolidation or share split of our common shares, a recapitalization or reclassification of our common shares, payment of dividends or distributions